|
1
|
Sharma A, Boise LH and Shanmugam M: Cancer
metabolism and the evasion of apoptotic cell death. Cancers
(Basel). 11:11442019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM and Yang
WS: Ferroptosis: An Iron-dependent form of nonapoptotic cell death.
Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galluzzi L, Vitale I, Aaronson SA, Abrams
JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews
DW, et al: Molecular mechanisms of cell death: Recommendations of
the Nomenclature Committee on Cell Death 2018. Cell Death Differ.
25:486–541. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Čepelak I, Dodig S and Dodig DČ:
Ferroptosis: Regulated cell death. Arh Hig Rada Toksikol.
71:99–109. 2020.PubMed/NCBI
|
|
5
|
Debela DT, Muzazu SG, Heraro KD, Ndalama
MT, Mesele BW, Haile DC, Kitui SK and Manyazewal T: New approaches
and procedures for cancer treatment: Current perspectives. SAGE
Open Med. 9:205031212110343662021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kishi Y, Hasegawa K, Sugawara Y and Kokudo
N: Hepatocellular carcinoma: Current management and future
development-improved outcomes with surgical resection. Int J
Hepatol. 2011:7281032011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yiannikourides A and Latunde-Dada GO: A
short review of iron metabolism and pathophysiology of iron
disorders. Medicines (Basel). 6:852019.PubMed/NCBI
|
|
8
|
Camaschella C, Nai A and Silvestri L: Iron
metabolism and iron disorders revisited in the hepcidin era.
Haematologica. 105:260–272. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao Z: Iron and oxidizing species in
oxidative stress and Alzheimer's disease. Aging Med (Milton).
2:82–87. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kotla NK, Dutta P, Parimi S and Das NK:
The role of ferritin in health and disease: Recent advances and
understandings. Metabolites. 12:6092022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Knovich MA, Storey JA, Coffman LG, Torti
SV and Torti FM: Ferritin for the clinician. Blood Rev. 23:95–104.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abbaspour N, Hurrell R and Kelishadi R:
Review on iron and its importance for human health. Iran J Pediatr.
19:164–174. 2014.
|
|
13
|
Fillebeen C, Charlebois E, Wagner J,
Katsarou A, Mui J, Vali H, Garcia-Santos D, Ponka P, Presley J and
Pantopoulos K: Transferrin receptor 1 controls systemic iron
homeostasis by fine-tuning hepcidin expression to hepatocellular
iron load. Blood. 133:344–355. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Obeagu EI and Tanko MSM: Iron metabolism
in breast cancer: Mechanisms and therapeutic implications: A
narrative review. Ann Med Surg (Lond). 87:3403–3409. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singh B, Arora S, Agrawal P and Gupta S:
Hepcidin: A novel peptide hormone regulating iron metabolism. Clin
Chim Acta. 412:823–830. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nemeth E and Ganz T: The role of hepcidin
in iron metabolism. Acta Haematol. 122:78–86. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shan Z, Wei Z and Shaikh ZA: Suppression
of ferroportin expression by cadmium stimulates proliferation, EMT,
and migration in Triple-negative breast cancer cells. Toxicol Appl
Pharmacol. 356:36–43. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Belvin BR and Lewis JP: Ferroportin
depletes iron needed for cell cycle progression in head and neck
squamous cell carcinoma. Front Oncol. 12:10254342023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grillo AS, SantaMaria AM, Kafina MD,
Cioffi AG, Huston NC, Han M, Seo YA, Yien YY, Nardone C, Menon AV,
et al: Restored iron transport by a small molecule promotes
absorption and hemoglobinization in animals. Science. 356:608–616.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Skjørringe T, Burkhart A, Johnsen K and
Moos T: Divalent metal transporter 1 (DMT1) in the brain:
Implications for a role in iron transport at the blood-brain
barrier, and neuronal and glial pathology. Front Mol Neurosci.
8:192015.PubMed/NCBI
|
|
21
|
Song Q, Peng S, Sun Z, Heng X and Zhu X:
Temozolomide drives ferroptosis via a DMT1-dependent pathway in
glioblastoma cells. Yonsei Med J. 62:8432021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ursini F and Maiorino M: Lipid
peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic
Biol Med. 152:175–185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aquilano K, Baldelli S and Ciriolo MR:
Glutathione: New roles in redox signaling for an old antioxidant.
Front Pharmacol. 5:1962014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu SC: Glutathione synthesis. Biochim
Biophys Acta. 1830:3143–3153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu M, Zhu W and Pei D: System Xc-: A key
regulatory target of ferroptosis in cancer. Invest New Drugs.
39:1123–1131. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lewerenz J, Hewett SJ, Huang Y, Lambros
MP, Gout PW, Kalivas PW, Massie A, Smolders IJ, Methner A, Pergande
M, et al: The cystine/glutamate antiporter system x(c)(−) in health
and disease: From molecular mechanisms to novel therapeutic
opportunities. Antioxid Redox Signal. 18:522–555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Koppula P, Li Z and Gan B: Cystine
transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient
dependency, and cancer therapy. Protein Cell. 12:599–620. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee J and Roh J: SLC7A11 as a gateway of
metabolic perturbation and ferroptosis vulnerability in cancer.
Antioxidants (Basel). 11:24442022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma Q: Role of NRF2 in oxidative stress and
toxicity. Annu Rev Pharmacol Toxicol. 53:401–426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kilberg MS, Shan J and Su N:
ATF4-dependent transcription mediates signaling of amino acid
limitation. Trends Endocrinol Metab. 20:436–443. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen D, Fan Z, Rauh M, Buchfelder M,
Eyupoglu IY and Savaskan NE: ATF4 promotes angiogenesis and
neuronal cell death and confers ferroptosis in a xCT-dependent
manner. Oncogene. 36:5593–5608. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Shi J, Liu X, Li F, Gong Z,
Koppula P, Sirohi K, Xu L, Wei Y, Lee H, et al: BAP1 links
metabolic regulation of ferroptosis to tumour suppression. Nat Cell
Biol. 20:1181–1192. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Lu Y, Zhang X, Cui W, Liu Y, Sun
Q, He Q, Zhao S, Zhang G, Wang Y, et al: Epigenetic regulation of
ferroptosis by H2B monoubiquitination and p53. EMBO Rep.
20:e475632019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Y, Zhao Y, Wang H, Zhang C, Wang M,
Yang Y, Xu X and Hu Z: Histone demethylase KDM3B protects against
ferroptosis by upregulating SLC7A11. FEBS Open Bio. 10:637–643.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsuchihashi K, Okazaki S, Ohmura M,
Ishikawa M, Sampetrean O, Onishi N, Wakimoto H, Yoshikawa M,
Seishima R, Iwasaki Y, et al: The EGF receptor promotes the
malignant potential of glioma by regulating amino acid transport
system xc(−). Cancer Res. 76:2954–2963. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu T, Jiang L, Tavana O and Gu W: The
deubiquitylase OTUB1 mediates ferroptosis via stabilization of
SLC7A11. Cancer Res. 79:1913–1924. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dixon SJ, Patel DN, Welsch M, Skouta R,
Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS
and Stockwell BR: Pharmacological inhibition of cystine-glutamate
exchange induces endoplasmic reticulum stress and ferroptosis.
Elife. 3:e025232014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gao M, Monian P, Quadri N, Ramasamy R and
Jiang X: Glutaminolysis and transferrin regulate ferroptosis. Mol
Cell. 59:298–308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang WS, Sriramaratnam R, Welsch M,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang Y, Lin J, Guo S, Xue X, Wang Y, Qiu
S, Cui J, Ma L, Zhang X and Wang J: RRM2 protects against
ferroptosis and is a tumor biomarker for liver cancer. Cancer Cell
Int. 20:162020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cramer SL, Saha A, Liu J, Tadi S, Tiziani
S, Yan W, Triplett K, Lamb C, Alters SE, Rowlinson SW, et al:
Systemic depletion of L-cyst(e)ine with cyst(e)inase increases
reactive oxygen species and suppresses tumor growth. Nat Med.
23:120–127. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sbodio JI, Snyder SH and Paul BD:
Regulators of the transsulfuration pathway. Br J Pharmacol.
176:583–593. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hayano M, Yang W, Corn CK, Pagano NC and
Stockwell BR: Loss of cysteinyl-tRNA synthetase (CARS) induces the
transsulfuration pathway and inhibits ferroptosis induced by
cystine deprivation. Cell Death Differ. 23:270–278. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Weaver K and Skouta R: The selenoprotein
glutathione peroxidase 4: From molecular mechanisms to novel
therapeutic opportunities. Biomedicines. 10:8912022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tuo Q, Masaldan S, Southon A, Mawal C,
Ayton S, Bush AI, Lei P and Belaidi AA: Characterization of
selenium compounds for anti-ferroptotic activity in neuronal cells
and after cerebral ischemia-reperfusion injury. Neurotherapeutics.
18:2682–2691. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hao S, Liang B, Huang Q, Dong S, Wu Z, He
W and Shi M: Metabolic networks in ferroptosis (Review). Oncol
Lett. 16:5279–5287. 2018.
|
|
47
|
Zheng J and Conrad M: The metabolic
underpinnings of ferroptosis. Cell Metab. 32:920–937. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shin D, Kim EH, Lee J and Roh J: Nrf2
inhibition reverses resistance to GPX4 inhibitor-induced
ferroptosis in head and neck cancer. Free Radic Biol Med.
129:454–462. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Alim I, Caulfield JT, Chen Y, Swarup V,
Geschwind DH, Ivanova E, Seravalli J, Ai Y, Sansing LH, SteMarie
EJ, et al: Selenium drives a transcriptional adaptive program to
block ferroptosis and treat stroke. Cell. 177:1262–1279.e25. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang Y, Swanda RV, Nie L, Liu X, Wang C,
Lee H, Lei G, Mao C, Koppula P, Cheng W, et al: mTORC1 couples
cyst(e)ine availability with GPX4 protein synthesis and ferroptosis
regulation. Nat Commun. 12:15892021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chaudhary N, Choudhary BS, Shah S, Khapare
N, Dwivedi N, Gaikwad A, Joshi N, Raichanna J, Basu S, Gurjar M, et
al: Lipocalin 2 expression promotes tumor progression and therapy
resistance by inhibiting ferroptosis in colorectal cancer. Int J
Cancer. 149:1495–1511. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li F, Long H, Zhou Z, Luo H, Xu S and Gao
L: System Xc-/GSH/GPX4 axis: An important antioxidant system for
the ferroptosis in drug-resistant solid tumor therapy. Front
Pharmacol. 13:9102922022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kerins M, Milligan JF, Wohlschlegel JA and
Ooi A: Fumarate hydratase inactivation in hereditary leiomyomatosis
and renal cell cancer is synthetic lethal with ferroptosis
induction. Cancer Sci. 109:2757–2766. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cui C, Yang F and Li Q: Post-translational
modification of GPX4 is a promising target for treating
ferroptosis-related diseases. Front Mol Biosci. 9:9015652022.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Grossman E, Ward CC, Spradlin JN, Bateman
LA, Huffman TR, Miyamoto DK, Kleinman JI and Nomura DK: Covalent
ligand discovery against druggable hotspots targeted by anticancer
natural products. Cell Chem Biol. 24:1368–1376.e4. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yang L, Chen X, Yang Q, Chen J, Huang Q,
Yao L, Ding Y, Wu J, Zhang P, Tang D, et al: Broad spectrum
deubiquitinase inhibition induces both apoptosis and ferroptosis in
cancer cells. Front Oncol. 10:9492020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhu S, Zhang Q, Sun X, Zeh HJ, Lotze MT,
Kang R and Tang D: HSPA5 regulates ferroptotic cell death in cancer
cells. Cancer Res. 77:2064–2077. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yang WS, Kim KJ, Gaschler MM, Patel MM,
Shchepinov MS and Stockwell BR: Peroxidation of polyunsaturated
fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci
USA. 113:E4966–E4975. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Viswanathan VS, Ryan M, Dhruv HD, Gill S,
Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada
K, Aguirre AJ, et al: Dependency of a therapy-resistant state of
cancer cells on a lipid peroxidase pathway. Nature. 547:453–457.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kagan VE, Mao G, Qu F, Angeli JPF, Doll S,
Croix C, Dar HH, Liu B, Tyurin VA, Ritov VB, et al: Oxidized
arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem
Biol. 13:81–90. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Dixon SJ, Winter GE, Musavi L, Lee ED,
Snijder B, Rebsamen M, Superti-Furga G and Stockwell BR: Human
haploid cell genetics reveals roles for lipid metabolism genes in
nonapoptotic cell death. ACS Chem Biol. 10:1604–1609. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Doll S, Freitas FP, Shah R, Aldrovandi M,
Da Silva MC, Ingold I, Grocin AG, Da Silva TNX, Panzilius E, Scheel
C, et al: FSP1 is a glutathione-independent ferroptosis suppressor.
Nature. 575:693–698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Snaebjornsson MT, Janaki-Raman S and
Schulze A: Greasing the wheels of the cancer machine: The role of
lipid metabolism in cancer. Cell Metab. 31:62–76. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Sun Y, Xue Z, Huang T, Che X and Wu G:
Lipid metabolism in ferroptosis and Ferroptosis-based cancer
therapy. Front Oncol. 12:9416182022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lee JY, Nam M, Son H, Hyun K, Jang SY, Kim
JW, Kim MW, Jung Y, Jang E, Yoon S, et al: Polyunsaturated fatty
acid biosynthesis pathway determines ferroptosis sensitivity in
gastric cancer. Proc Natl Acad Sci USA. 117:32433–32442. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kim JW, Lee J, Oh M and Lee EW: An
integrated view of lipid metabolism in ferroptosis revisited via
lipidomic analysis. Exp Mol Med. 55:1620–1631. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lee J, Kim WK, Bae K, Lee SC and Lee EW:
Lipid metabolism and ferroptosis. Biology (Basel).
10:1842021.PubMed/NCBI
|
|
68
|
Song Z, Xiaoli AM and Yang F: Regulation
and metabolic significance of de novo lipogenesis in adipose
tissues. Nutrients. 10:13832018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Carracedo A, Cantley LC and Pandolfi PP:
Cancer metabolism: Fatty acid oxidation in the limelight. Nat Rev
Cancer. 13:227–232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Roehrig F and Schulze A: The multifaceted
roles of fatty acid synthesis in cancer. Nat Rev Cancer.
16:732–749. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Olzmann JA and Carvalho P: Dynamics and
functions of lipid droplets. Nat Rev Mol Cell Biol. 20:137–155.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Cruz ALS, Barreto EA, Fazolini NPB, Viola
JPB and Bozza PT: Lipid droplets: Platforms with multiple functions
in cancer hallmarks. Cell Death Dis. 6:1052020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Guerrero-Rodriguez S, Mata-Cruz C,
Pérez-Tapia SM and Velasco-Velázquez MA: Role of CD36 in cancer
progression, stemness, and targeting. Front Cell Dev Biol.
10:10790762022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Pascual G, Avgustinova A, Mejetta S,
Martín M, Castellanos A, Attolini CS, Berenguer A, Prats N, Toll A,
Hueto JA, et al: Targeting metastasis-initiating cells through the
fatty acid receptor CD36. Nature. 541:41–45. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Veglia F, Tyurin VA, Di Blasi M, De Leo A,
Kossenkov AV, Donthireddy L, To TKJ, Schug ZT, Basu S, Wang F, et
al: Fatty acid transport protein 2 reprograms neutrophils in
cancer. Nature. 569:73–78. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zielinski ZAM and Pratt DA: Cholesterol
autoxidation revisited: Debunking the dogma associated with the
most vilified of lipids. J Am Chem Soc. 138:6932–6935. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Chushi L, Wu W, Xie K, Feng Y, Xie N and
Chen X: HMGCR is up-regulated in gastric cancer and promotes the
growth and migration of the cancer cells. Gene. 587:42–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Deng R, Fu L, Liang H, Ai X, Liu F, Li N,
Wu L, Li S, Yang X, Lin Y, et al: Inhibition of mitochondrial
complex I induces mitochondrial ferroptosis by regulating CoQH2
levels in cancer. Cell Death Dis. 16:2542025. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee
H, Koppula P, Wu S, Zhuang L, Fang B, et al: DHODH-mediated
ferroptosis defence is a targetable vulnerability in cancer.
Nature. 593:586–590. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wu J, Wang Y, Jiang R, Xue R, Yin X, Wu M
and Meng Q: Ferroptosis in liver disease: New insights into disease
mechanisms. Cell Death Discov. 7:2762021. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhan M, Ding Y, Huang S, Liu Y, Xiao J, Yu
H, Lu L and Wang X: Lysyl oxidase-like 3 restrains mitochondrial
ferroptosis to promote liver cancer chemoresistance by stabilizing
dihydroorotate dehydrogenase. Nat Commun. 14:31232023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kraft VAN, Bezjian CT, Pfeiffer S,
Ringelstetter L, Müller C, Zandkarimi F, Merl-Pham J, Bao X,
Anastasov N, Kössl J, et al: GTP cyclohydrolase
1/tetrahydrobiopterin counteract ferroptosis through lipid
remodeling. ACS Cent Sci. 6:41–53. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Hu Q, Wei W, Wu D, Huang F, Li M, Li W,
Yin J, Peng Y, Lu Y, Zhao Q, et al: Blockade of GCH1/BH4 axis
activates ferritinophagy to mitigate the resistance of colorectal
cancer to Erastin-induced ferroptosis. Front Cell Dev Biol.
10:8103272022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Lim JKM, Stölting F, Levy T, Thewes L,
Picard D, Tishina S, Zhang H, Lewandowska O, Reiff T, Remke M, et
al: Oncogenic RAS signaling suppresses ferroptosis via
transcriptional upregulation of GCH1. bioRxiv. Jan
29–2024.doi.org/10.1101/2024.01.27.577524.
|
|
85
|
Cao J, Chen X, Chen L, Lu Y, Wu Y, Deng A,
Pan F, Huang H, Liu Y, Li Y, et al: DHODH-mediated mitochondrial
redox homeostasis: A novel ferroptosis regulator and promising
therapeutic target. Redox Biol. 85:1037882025. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Mazdak H, Yazdekhasti F, Movahedian A,
Mirkheshti N and Shafieian M: The comparative study of serum iron,
copper, and zinc levels between bladder cancer patients and a
control group. Int Urol Nephrol. 42:89–93. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
An WX, Gupta R, Zhai K, Wang YR, Xu WH and
Cui Y: Current and potential roles of ferroptosis in bladder
cancer. Curr Med Sci. 44:51–63. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kong N, Chen X, Feng J, Duan T, Liu S, Sun
X, Chen P, Pan T, Yan L, Jin T, et al: Baicalin induces ferroptosis
in bladder cancer cells by downregulating FTH1. Acta Pharm Sin B.
11:4045–4054. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Shimada K, Skouta R, Kaplan A, Yang WS,
Hayano M, Dixon SJ, Brown LM, Valenzuela CA, Wolpaw AJ and
Stockwell BR: Global survey of cell death mechanisms reveals
metabolic regulation of ferroptosis. Nat Chem Biol. 12:497–503.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Stepanic V and Kucerova-Chlupacova M:
Review and chemoinformatic analysis of ferroptosis modulators with
a focus on natural plant products. Molecules. 28:4752023.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Xiang Y, Chen X, Wang W, Zhai L, Sun X,
Feng J, Duan T, Zhang M, Pan T, Yan L, et al: Natural product
erianin inhibits bladder cancer cell growth by inducing ferroptosis
via NRF2 inactivation. Front Pharmacol. 12:7755062021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Sun Y, Berleth N, Wu W, Schlutermann D,
Deitersen J, Stuhldreier F, Berning L, Friedrich A, Akgun S,
Mendiburo MJ, et al: Fin56-induced ferroptosis is supported by
autophagy-mediated GPX4 degradation and functions synergistically
with mTOR inhibition to kill bladder cancer cells. Cell Death Dis.
12:10282021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhang X, Sui S, Wang L, Li H, Zhang L, Xu
S and Zheng X: Inhibition of tumor propellant glutathione
peroxidase 4 induces ferroptosis in cancer cells and enhances
anticancer effect of cisplatin. J Cell Physiol. 235:3425–3437.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Lachaier E, Louandre C, Godin C, Saidak Z,
Baert M, Diouf M, Chauffert B and Galmiche A: Sorafenib induces
ferroptosis in human cancer cell lines originating from different
solid tumors. Int J Oncol. 34:6417–6422. 2014.
|
|
95
|
Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R
and Tang D: Activation of the p62-Keap1-NRF2 pathway protects
against ferroptosis in hepatocellular carcinoma cells. Hepatology.
63:173–184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Chiang S, Chen S and Chang L: A dual role
of HEME oxygenase-1 in cancer cells. Int J Mol Sci. 20:392019.
View Article : Google Scholar
|
|
97
|
Sun X, Niu X, Chen R, He W, Chen D, Kang R
and Tang D: Metallothionein-1G facilitates sorafenib resistance
through inhibition of ferroptosis. Hepatology. 64:488–500. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Bai T, Lei P, Zhou H, Liang R, Zhu R, Wang
W, Zhou L and Sun Y: Sigma-1 receptor protects against ferroptosis
in hepatocellular carcinoma cells. J Cell Mol Med. 23:7349–7359.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Yang F, Li J, Deng H, Wang Y, Lei C, Wang
Q, Jin X, Liang L, Xia J, Pan X, et al: GSTZ1-1 deficiency
activates NRF2/IGF1R axis in HCC via accumulation of oncometabolite
succinylacetone. EMBO J. 38:e1019642019. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Wang Q, Cheng B, Qin X, Gao Q, Huang A,
Wang K and Tang N: GSTZ1 sensitizes hepatocellular carcinoma cells
to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
Cell Death Dis. 12:4262021. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Louandre C, Marcq I, Bouhlal H, Lachaier
E, Godin C, Saidak Z, François C, Chatelain D, Debuysscher V,
Barbare J, et al: The retinoblastoma (Rb) protein regulates
ferroptosis induced by sorafenib in human hepatocellular carcinoma
cells. Cancer Lett. 356:971–977. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhang Y, Li J, Dong X, Meng D, Zhi X, Liu
Y and Yao L: PSAT1 regulated oxidation-reduction balance affects
the growth and prognosis of epithelial ovarian cancer. Onco Targets
Ther. 13:5443–5453. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Haga Y, Kanda T, Nakamura M, Nakamoto S,
Sasaki R, Takahashi K, Wu S and Yokosuka O: Overexpression of c-Jun
contributes to sorafenib resistance in human hepatoma cell lines.
PLoS One. 12:e01741532017. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Chen Y, Zhu G, Liu Y, Wu Q, Zhang X, Bian
Z, Zhang Y, Pan Q and Sun F: O-GlcNAcylated c-Jun antagonizes
ferroptosis via inhibiting GSH synthesis in liver cancer. Cell
Signal. 63:1093842019. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Gao R, Kalathur RKR, Coto-Llerena M, Ercan
C, Buechel D, Song S, Piscuoglio S, Dill MT, Camargo FD,
Christofori G, et al: YAP/TAZ and ATF4 drive resistance to
sorafenib in hepatocellular carcinoma by preventing ferroptosis.
EMBO Mol Med. 13:e143512021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wang K, Zhang Z, Tsai H, Liu Y, Gao J,
Wang M, Liu S, Cao X, Xu Z, Chen H, et al: Branched-chain amino
acid aminotransferase 2 regulates ferroptotic cell death in cancer
cells. Cell Death Differ. 28:1222–1236. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Qiu Y, Li H, Xie J, Qiao X and Wu J:
Identification of ABCC5 among ATP-binding cassette transporter
family as a new biomarker for hepatocellular carcinoma based on
bioinformatics analysis. Int J Gen Med. 14:7235–7246. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Huang W, Chen K, Lu Y, Zhang D, Cheng Y,
Li L, Huang W, He G, Liao H, Cai L, et al: ABCC5 facilitates the
acquired resistance of sorafenib through the inhibition of
SLC7A11-induced ferroptosis in hepatocellular carcinoma. Neoplasia.
23:1227–1239. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Byun J, Lee S, Kang G, Lee YR, Park SY,
Song I, Yun JW, Lee J, Choi Y and Park K: Macropinocytosis is an
alternative pathway of cysteine acquisition and mitigates
sorafenib-induced ferroptosis in hepatocellular carcinoma. J Exp
Clin Cancer Res. 41:22962022. View Article : Google Scholar
|
|
110
|
Lee JY, Kang ES, Kobayashi S, Homma T,
Sato H, Seo HG and Fujii J: The viability of primary hepatocytes is
maintained under a low cysteine-glutathione redox state with a
marked elevation in ophthalmic acid production. Exp Cell Res.
361:178–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Chen Y, Li L, Lan J, Yang C, Rao X, Zhao
J, Xing T, Ju G, Song G and Lou J: CRISPR screens uncover
protective effect of PSTK as a regulator of chemotherapy-induced
ferroptosis in hepatocellular carcinoma. Mol Cancer. 21:112022.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Liu Y, Fan X, Zhao Z and Shan XH: LncRNA
SLC7A11-AS1 contributes to lung cancer progression through
facilitating TRAIP expression by inhibiting miR-4775. Onco Targets
Ther. 13:6295–6302. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhang W, Sun Y, Bai L, Zhi L, Yang Y, Zhao
Q, Chen C, Qi Y, Gao W, He W, et al: RBMS1 regulates lung cancer
ferroptosis through translational control of SLC7A11. J Clin
Invest. 131:e1520672021. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Lu X, Kang N, Ling X, Pan M, Du W and Gao
S: MIR-27A-3P promotes non-small cell lung cancer through
SLC7A11-mediated ferroptosis. Front Oncol. 11:7593462021.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Gargalionis AN, Papavassiliou KA and
Papavassiliou AG: Implication of MTOR signaling in NSCLC:
Mechanisms and therapeutic perspectives. Cells. 12:20142023.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Ni J, Chen K, Zhang J and Zhang X:
Inhibition of GPX4 or mTOR overcomes resistance to lapatinib via
promoting ferroptosis in NSCLC cells. Biochem Biophys Res Commun.
567:154–160. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Li Y, Yan H, Xu X, Liu H, Wu C and Zhao L:
Erastin/sorafenib induces cisplatin-resistant non-small cell lung
cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway.
Oncol Lett. 19:323–333. 2020.PubMed/NCBI
|
|
118
|
Carlisle AE, Lee N, Matthew-Onabanjo AN,
Spears ME, Park SJ, Youkana D, Doshi MB, Peppers A, Li R, Joseph
AB, et al: Selenium detoxification is required for cancer-cell
survival. Nat Metab. 2:603–611. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Yu H, Yang C, Lei J, Guo S, Chen R, Li K,
Qu F, Tao K, Fu Y, Liu F, et al: Sulfasalazine-induced ferroptosis
in breast cancer cells is reduced by the inhibitory effect of
estrogen receptor on the transferrin receptor. Oncol Rep.
42:2650–2660. 2019.
|
|
120
|
Yadav P, Sharma P, Sundaram S, Venkatraman
G, Bera AK and Karunagaran D: SLC7A11/xCT is a target of miR-5096
and its restoration partially rescues miR-5096-mediated ferroptosis
and antitumor effects in human breast cancer cells. Cancer Lett.
522:211–224. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Sugezawa K, Morimoto M, Yamamoto M,
Matsumi Y, Nakayama Y, Hara K, Uejima C, Kihara K, Matsunaga T,
Tokuyasu N, et al: GPX4 regulates tumor cell proliferation via
suppressing ferroptosis and exhibits prognostic significance in
gastric cancer. Anticancer Res. 42:5719–5729. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Zeuner A, Todaro M, Stassi G and De Maria
R: Colorectal cancer stem cells: From the crypt to the clinic. Cell
Stem Cell. 15:692–705. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Hao S, Yu J, He W, Huang Q, Zhao Y, Liang
B, Zhang S, Wen Z, Dong S, Rao J, et al: Cysteine dioxygenase 1
mediates Erastin-induced ferroptosis in human gastric cancer cells.
Neoplasia. 19:1022–1032. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Ye G, Guan W, Cao Z, Guo W, Xiong G, Zhao
F, Feng M, Qiu J, Liu Y, Zhang MQ, et al: Integrative genomic
analysis of gemcitabine resistance in pancreatic cancer by
patient-derived xenograft models. Clin Cancer Res. 27:3383–3396.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Thummuri D, Khan S, Underwood PW, Zheng P,
Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A,
et al: Overcoming gemcitabine resistance in pancreatic cancer using
the BCL-XL-Specific degrader DT2216. Mol Cancer Ther. 21:184–192.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Wang H, Liu C, Zhao Y, Zhang W, Xu K, Li
D, Zhou Y, Li H, Xiao G, Lu B and Gao G: Inhibition of LONP1
protects against erastin-induced ferroptosis in pancreatic ductal
adenocarcinoma PANC1 cells. Biochem Biophys Res Commun.
522:1063–1068. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Wang Y, Wu X, Zhao R, Yu-Lin L, Zou W,
Chen J and Wang H: Overcoming cancer chemotherapy resistance by the
induction of ferroptosis. Drug Resist Updat. 66:1009162023.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Ludin A, Gur-Cohen S, Golan K, Kaufmann
KB, Itkin T, Medaglia C, Lu XJ, Ledergor G, Kollet O and Lapidot T:
Reactive oxygen species regulate hematopoietic stem cell
self-renewal, migration and development, as well as their bone
marrow microenvironment. Antioxid Redox Signal. 21:1605–1619. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Fischbacher A, von Sonntag C and Schmidt
TC: Hydroxyl radical yields in the Fenton process under various pH,
ligand concentrations and hydrogen peroxide/Fe(II) ratios.
Chemosphere. 182:738–744. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Rassool FV, Gaymes TJ, Omidvar N, Brady N,
Beurlet S, Pla M, Reboul M, Lea N, Chomienne C, Thomas NS, et al:
Reactive oxygen species, DNA damage, and error-prone repair: A
model for genomic instability with progression in myeloid leukemia?
Cancer Res. 67:8762–8771. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Hole PS, Zabkiewicz J, Munje C, Newton Z,
Pearn L, White P, Marquez N, Hills RK, Burnett AK, Tonks A and
Darley RL: Overproduction of NOX-derived ROS in AML promotes
proliferation and is associated with defective oxidative stress
signaling. Blood. 122:3322–3330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Fonseca-Nunes A, Jakszyn P and Agudo A:
Iron and cancer risk-a systematic review and meta-analysis of the
epidemiological evidence. Cancer Epidemiol Biomarkers Prev.
23:12–31. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Manz DH, Blanchette NL, Paul BT, Torti FM
and Torti SV: Iron and cancer: Recent insights. Ann N Y Acad Sci.
1368:149–161. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Long F, Lin Z, Long Q, Lu Z, Zhu K, Zhao M
and Yang M: CircZBTB46 protects acute myeloid leukemia cells from
ferroptotic cell death by upregulating SCD. Cancers (Basel).
15:4592023. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Aurelius J, Thorén FB, Akhiani AA, Brune
M, Palmqvist L, Hansson M, Hellstrand K and Martner A: Monocytic
AML cells inactivate antileukemic lymphocytes: Role of NADPH
oxidase/gp91(phox) expression and the PARP-1/PAR pathway of
apoptosis. Blood. 119:5832–5837. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Chen J, Lu WY, Zhao MF, Cao XL, Jiang YY,
Jin X, Xu P, Yuan TT, Zhang YC, Chai X, et al: Reactive oxygen
species mediated T lymphocyte abnormalities in an iron-overloaded
mouse model and iron-overloaded patients with myelodysplastic
syndromes. Ann Hematol. 96:1085–1095. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Liu Y, Du Z, Huang J, Li T, Zhang J, Li Y,
Yi W and Chen C: Ferroptosis in hematological malignant tumors.
Front Oncol. 13:11275262023. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Bai Y, Luo Y, Yuan Y, Li X, Jin J, Ping R,
Guo J, Jin L, Yu Y and Xiong Y: Ferroptosis: A novel therapeutic
warrior in the battle against leukemia. Apoptosis. 30:1776–1795.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Wei J, Xie Q, Liu X, Wan C, Wu W, Fang K,
Yao Y, Cheng P, Deng D and Liu Z: Identification the prognostic
value of glutathione peroxidases expression levels in acute myeloid
leukemia. Ann Transl Med. 8:6782020. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ma Z, Ye W, Huang X, Li X, Li F, Lin X, Hu
C, Wang J, Jin J, Zhu B and Huang J: The ferroptosis landscape in
acute myeloid leukemia. Aging (Albany NY). 15:13486–13503. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Yu Y, Yan Y, Niu F, Wang Y, Chen X, Su G,
Liu Y, Zhao X, Qian L, Liu P and Xiong Y: Ferroptosis: A cell death
connecting oxidative stress, inflammation and cardiovascular
diseases. Cell Death Discov. 7:1932021. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Liu X, Zhong S, Qiu K, Chen X, Wu W, Zheng
J, Liu Y, Wu H, Fan S, Nie D, et al: Targeting NRF2 uncovered an
intrinsic susceptibility of acute myeloid leukemia cells to
ferroptosis. Exp Hematol Oncol. 12:472023. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Xia J, Sun S, Jotte MR, Uy GL, Sorani E,
Abi Vainstein L, Shemesh Davish L, Caldwell KE, Hawkins WG and Link
DC: Combined inhibition of CXCR4 signaling and System
xc-transporter activity induces synthetic lethality in T-ALL cells
by suppressing GSH and inducing ferroptosis. Blood. 136 (Suppl
1):S372020. View Article : Google Scholar
|
|
144
|
Zhang W, Trachootham D, Liu J, Chen G,
Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W,
et al: Stromal control of cystine metabolism promotes cancer cell
survival in chronic lymphocytic leukaemia. Nat Cell Biol.
14:276–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Liu J, Xia X and Huang P: xCT: A critical
molecule that links cancer metabolism to redox signaling. Mol Ther.
28:2358–2366. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Birsen R, Larrue C, Decroocq J, Johnson N,
Guiraud N, Gotanegre M, Cantero-Aguilar L, Grignano E, Huynh T,
Fontenay M, et al: APR-246 induces early cell death by ferroptosis
in acute myeloid leukemia. Haematologica. 107:403–416. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Pardieu B, Pasanisi J, Ling F, Dal Bello
R, Penneroux J, Su A, Joudinaud R, Chat L, Wu HC, Duchmann M, et
al: Cystine uptake inhibition potentiates front-line therapies in
acute myeloid leukemia. Leukemia. 36:1585–1595. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Rashkovan M and Ferrando A: Metabolic
dependencies and vulnerabilities in leukemia. Genes Dev.
33:1460–1474. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Zheng X, Jin X, Ye F, Liu X, Yu B, Li Z,
Zhao T, Chen W, Liu X, Di C and Li Q: Ferroptosis: A novel
regulated cell death participating in cellular stress response,
radiotherapy, and immunotherapy. Exp Hematol Oncol. 12:652023.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Dächert J, Schoeneberger H, Rohde K and
Fulda S: RSL3 and erastin differentially regulate redox signaling
to promote Smac mimetic-induced cell death. Oncotarget.
7:63779–63792. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Brown RAM, Richardson KL, Kabir TD,
Trinder D, Ganss R and Leedman PJ: Altered iron metabolism and
impact in cancer biology, metastasis, and immunology. Front Oncol.
10:4762020. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Yang N, Tan S, Ng SC, Shi Y, Zhou J, Tan
KSW, Wong WF and Shen H: Artesunate induces cell death in human
cancer cells via enhancing lysosomal function and lysosomal
degradation of ferritin. J Biol Chem. 289:33425–33441. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Ooko E, Saeed ME, Kadioglu O, Sarvi S,
Colak M, Elmasaoudi K, Janah R, Greten HJ and Efferth T:
Artemisinin derivatives induce iron-dependent cell death
(ferroptosis) in tumor cells. Phytomedicine. 22:1045–1054. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Santana-Codina N and Mancias JD: The role
of NCOA4-mediated ferritinophagy in health and disease.
Pharmaceuticals (Basel). 11:1142018. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C,
Dai X, Li Z and Wu G: Ferroptosis: A novel antitumor action for
cisplatin. Cancer Res Treat. 50:445–460. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Wen RJ, Dong X, Zhuang HW, Pang FX, Ding
SC, Li N, Mai YX, Zhou ST, Wang JY and Zhang JF: Baicalin induces
ferroptosis in osteosarcomas through a novel Nrf2/xCT/GPX4
regulatory axis. Phytomedicine. 116:1548812023. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Tang Z, Huang Z, Huang Y, Chen Y, Huang M,
Liu H, Ye Q, Zhao J and Jia B: Ferroptosis: The silver lining of
cancer therapy. Front Cell Dev Biol. 9:7658592021. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Shintoku R, Takigawa Y, Yamada K, Kubota
C, Yoshimoto Y, Takeuchi T, Koshiishi I and Torii S:
Lipoxygenase-mediated generation of lipid peroxides enhances
ferroptosis induced by erastin and RSL3. Cancer Sci. 108:2187–2194.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Chu B, Kon N, Chen D, Li T, Liu T, Jiang
L, Song S, Tavana O and Gu W: ALOX12 is required for p53-mediated
tumour suppression through a distinct ferroptosis pathway. Nat Cell
Biol. 21:579–591. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Zou Y, Li H, Graham E, Deik A, Eaton JK,
Wang W, Sandoval-Gomez G, Clish CB, Doench JG and Schreiber SL:
Cytochrome P450 oxidoreductase contributes to phospholipid
peroxidation in ferroptosis. Nat Chem Biol. 16:302–309. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Zhou Y, Tashiro J, Kamatani S, Irie N,
Suzuki A, Ishikawa T, Warita K, Oltvai ZN and Warita T: HMG-CoA
reductase degrader, SR-12813, counteracted statin-induced
upregulation of HMG-CoA reductase and augmented the anticancer
effect of atorvastatin. Biochem Biophys Res Commun. 677:13–19.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Yang J, Xu J, Zhang B, Tan Z, Meng Q, Hua
J, Liu J, Wang W, Shi S, Yu X and Liang C: Ferroptosis: At the
crossroad of gemcitabine resistance and tumorigenesis in pancreatic
cancer. Int J Mol Sci. 22:109442021. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Chen L, Sun R and Fang K: Erianin inhibits
tumor growth by promoting ferroptosis and inhibiting invasion in
hepatocellular carcinoma through the JAK2/STAT3/SLC7A11 pathway.
Pathol Int. 74:119–128. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Zheng Y, Zheng Y, Chen H, Tan X, Zhang G,
Kong M, Jiang R, Yu H, Shan K, Liu J, et al: Erianin triggers
ferroptosis in colorectal cancer cells by facilitating the
ubiquitination and degradation of GPX4. Phytomedicine.
139:1564652025. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Tian XY, Han R, Huang QY, Zhou MY, Luo B,
Chen XR and Xu JC: Erianin inhibits oral cancer cell growth,
migration, and invasion via the Nrf2/HO-1/GPX4 pathway. Asian Pac J
Trop Biomed. 12:4372022. View Article : Google Scholar
|
|
166
|
Yagoda N, Von Rechenberg M, Zaganjor E,
Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM,
Boniface JJ, et al: RAS-RAF-MEK-dependent oxidative cell death
involving voltage-dependent anion channels. Nature. 447:865–869.
2007. View Article : Google Scholar
|
|
167
|
Zhao J, Xu B, Xiong Q, Feng Y and Du H:
Erastin-induced ferroptosis causes physiological and pathological
changes in healthy tissues of mice. Mol Med Rep. 24:7132021.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Yu M, Gai C, Li Z, Ding D, Zheng J, Zhang
W, Lv S and Li W: Targeted exosome-encapsulated erastin induced
ferroptosis in triple negative breast cancer cells. Cancer Sci.
110:3173–3182. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Sun S, Shen J, Jiang J, Wang F and Min J:
Targeting ferroptosis opens new avenues for the development of
novel therapeutics. Signal Transduct Target Ther. 8:3722023.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Bersuker K, Hendricks JM, Li Z, Magtanong
L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, et al:
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit
ferroptosis. Nature. 575:688–692. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Zhao Y, Liu J, Wang S and Li X: Role of
non-coding RNA-regulated ferroptosis in colorectal cancer. Cell
Death Discov. 11:3152025. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Ghosal J, Sinchana VK and Chakrabarty S:
Ferroptosis meets microRNAs: A new frontier in anticancer therapy.
Free Radic Biol Med. 226:266–278. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Ju Y, Lv Y, Liu X, Lu J, Shi Y, Guo H, Xu
S, Tian J, Yang J and Zhong J: Role of long non-coding RNAs in the
regulation of ferroptosis in tumors. Front Immunol. 16:15685672025.
View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Yang R, Ma L, Wan J, Li Z, Yang Z, Zhao Z
and Ming L: Ferroptosis-associated circular RNAs: Opportunities and
challenges in the diagnosis and treatment of cancer. Front Cell Dev
Biol. 11:11603812023. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Lyu N, Zeng Y, Kong Y, Chen Q, Deng H, Ou
S, Bai Y, Tang H, Wang X and Zhao M: Ferroptosis is involved in the
progression of hepatocellular carcinoma through the
circ0097009/miR-1261/SLC7A11 axis. Ann Transl Med. 9:6752021.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Pan X, Chen K, Gao W, Xu M, Meng F, Wu M,
Wang ZQ, Li YQ, Xu W, Zhang M and Luo Y: Circular RNA circBNC2
inhibits tumorigenesis by modulating ferroptosis and acts as a
nanotherapeutic target in prostate cancer. Mol Cancer. 24:292025.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Sleire L, Skeie BS, Netland IA, Førde HE,
Dodoo E, Selheim F, Leiss L, Heggdal JI, Wang J and Enger PØ: Drug
repurposing: Sulfasalazine sensitizes gliomas to gamma knife
radiosurgery by blocking cystine uptake through system Xc-, leading
to glutathione depletion. Oncogene. 34:5951–5959. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Li Z, Dai HQ, Huang XW, Feng J, Deng JH,
Wang ZX, Yang XM, Liu YJ, Wu Y, Chen PH, et al: Artesunate
synergizes with sorafenib to induce ferroptosis in hepatocellular
carcinoma. Acta Pharm Sin B. 42:301–310. 2021. View Article : Google Scholar
|
|
179
|
Li H, Yu Y, Liu Y, Luo Z, Law BYK, Zheng
Y, Huang X and Li W: Ursolic acid enhances the antitumor effects of
sorafenib associated with Mcl-1-related apoptosis and
SLC7A11-dependent ferroptosis in human cancer. Pharmacol Res.
182:1063062022. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Wang H, Zhang Z, Ruan S, Qiu Y, Chen Y,
Cui J, Wang X, Huang S and Hou B: Regulation of iron metabolism and
ferroptosis in cancer stem cells. Front Oncol. 13:12515612023.
View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Campanella A, Santambrogio P, Fontana F,
Frenquelli M, Cenci S, Marcatti M, Sitia R, Tonon G and Camaschella
C: Iron increases the susceptibility of multiple myeloma cells to
bortezomib. Haematologica. 98:971–979. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Chekhun VF, Lukyanova NY, Burlaka AP,
Bezdenezhnykh NA, Shpyleva SI, Tryndyak VP, Beland FA and Pogribny
IP: Iron metabolism disturbances in the MCF-7 human breast cancer
cells with acquired resistance to doxorubicin and cisplatin. Int J
Oncol. 43:1481–1486. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Habib E, Linher-Melville K, Lin H and
Singh G: Expression of xCT and activity of system xc(−) are
regulated by NRF2 in human breast cancer cells in response to
oxidative stress. Redox Biol. 5:33–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Hangauer MJ, Viswanathan VS, Ryan MJ, Bole
D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL,
et al: Drug-tolerant persister cancer cells are vulnerable to GPX4
inhibition. Nature. 551:247–250. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Lei G, Mao C, Yan Y, Li Z and Gan B:
Ferroptosis, radiotherapy, and combination therapeutic strategies.
Protein Cell. 12:836–857. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Ye LF, Chaudhary K, Zandkarimi F, Harken
A, Kinslow CJ, Upadhyayula PS, Dovas A, Higgins D, Tan H, Zhang Y,
et al: Radiation-induced lipid peroxidation triggers ferroptosis
and synergizes with ferroptosis inducers. ACS Chem Biol.
15:469–484. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Lei G, Zhang Y, Koppula P, Liu X, Zhang J,
Lin SH, Ajani JA, Xiao Q, Liao Z, Wang H and Gan B: The role of
ferroptosis in ionizing radiation-induced cell death and tumor
suppression. Cell Res. 30:146–162. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Lin Z, Zou S and Wen K: The crosstalk of
CD8+ T cells and ferroptosis in cancer. Front Immunol.
14:12554432024. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Zheng Y, Sun L, Guo J and Ma J: The
crosstalk between ferroptosis and anti-tumor immunity in the tumor
microenvironment: Molecular mechanisms and therapeutic controversy.
Cancer Commun (Lond). 43:1071–1096. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Xia W, Lv Y, Zou Y, Kang Z, Li Z, Tian J,
Zhou H, Su W and Zhong J: The role of ferroptosis in colorectal
cancer and its potential synergy with immunotherapy. Front Immunol.
15:15267492025. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Tao Q, Liu N, Wu J, Chen J, Chen X and
Peng C: Mefloquine enhances the efficacy of anti-PD-1 immunotherapy
via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors. J
Immunother Cancer. 12:e0085542024. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Wang T, Li Z, Lei J, Zhang Y, Tong Y, Guan
X and Wang S: RGD peptide-functionalized micelles loaded with
crocetin ameliorate doxorubicin-induced cardiotoxicity. Int J Pharm
X. 9:1003262025.PubMed/NCBI
|
|
193
|
Zhang T, Gu F, Lin W, Shao H, Jiang A and
Guan X: Boosting cancer immunotherapy: Drug delivery systems
leveraging ferroptosis and immune checkpoint blockade. Front
Immunol. 16:16112992025. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Manivasagan P, Joe A, Han H, Thambi T,
Selvaraj M, Chidambaram K, Kim J and Jang E: Recent advances in
multifunctional nanomaterials for photothermal-enhanced
Fenton-based chemodynamic tumor therapy. Mater Today Bio.
13:1001972022. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Ma P, Xiao H, Chang Y, Liu J, Cheng Z,
Song H, Zhang X, Li C, Wang J, Gu Z and Lin J: Enhanced cisplatin
chemotherapy by iron oxide nanocarrier-mediated generation of
highly toxic reactive oxygen species. Nano Lett. 17:928–937. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Luo L, Wang H, Tian W, Li X, Zhu Z, Huang
R and Luo H: Targeting ferroptosis-based cancer therapy using
nanomaterials: Strategies and applications. Theranostics.
11:9937–9952. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Yang J, Gong Y, Sontag DP, Corbin IR and
Minuk GY: Effects of Low-density lipoprotein docosahexaenoic acid
nanoparticles on cancer stem cells isolated from human hepatoma
cell lines. Mol Biol Rep. 45:1023–1036. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Poggio M, Tao H, Pai CC, Chu B, Belair CD,
Chang A, Montabana E, Lang UE, Fu Q, Fong L and Blelloch R:
Suppression of exosomal PD-L1 induces systemic antitumor immunity
and memory. Cell. 177:414–427.e13. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Jelinek A, Heyder L, Daude M, Plessner M,
Krippner S, Grosse R, Diederich WE and Culmsee C: Mitochondrial
rescue prevents glutathione peroxidase-dependent ferroptosis. Free
Radic Biol Med. 117:45–57. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Wu J, Feng Z, Chen L, Li Y, Bian H, Geng
J, Zheng ZH, Fu X, Pei Z, Qin Y, et al: TNF antagonist sensitizes
synovial fibroblasts to ferroptotic cell death in Collagen-induced
arthritis mouse models. Nat Commun. 13:6762022. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Qin LY, Guan P, Wang JX, Chen Y, Zhao YS,
Yang SC, Guo YJ, Wang N and Ji ES: Therapeutic potential of
Astragaloside IV against Adriamycin-induced renal damage in rats
via ferroptosis. Front Pharmacol. 13:8125942022. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Eaton JK, Ruberto RA, Kramm A, Viswanathan
VS and Schreiber SL: Diacylfuroxans are masked nitrile oxides that
inhibit GPX4 covalently. J Am Chem Soc. 141:20407–20415. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Firtina Karagonlar Z, Koc D, Iscan E,
Erdal E and Atabey N: Elevated hepatocyte growth factor expression
as an autocrine c-Met activation mechanism in acquired resistance
to sorafenib in hepatocellular carcinoma cells. Cancer Sci.
107:407–416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Liu K, Huang L, Qi S, Liu S, Xie W, Du L,
Cui J, Zhang X, Zhang B, Liu L, et al: Ferroptosis: The
entanglement between traditional drugs and nanodrugs in tumor
therapy. Adv Healthc Mater. 12:e22030852023. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Singh M, Arora HL, Naik R, Joshi S,
Sonawane K, Sharma NK and Sinha BK: Ferroptosis in cancer:
Mechanism and therapeutic potential. Int J Mol Sci. 26:38522025.
View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Ojo OA, Grant S, Nwafor-Ezeh PI,
Maduakolam-Aniobi TC, Akinborode TI, Ezenabor EH and Ojo AB:
Ferroptosis as the new approach to cancer therapy. Cancer Treat Res
Commun. 43:1009132025.PubMed/NCBI
|
|
207
|
Ubellacker JM and Dixon SJ: Prospects for
ferroptosis therapies in cancer. Nat Cancer. 6:13262025. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Hino K, Nishina S and Yanatori I:
Ferroptosis: Biology and role in liver disease. J Gastroenterol.
Sep 18–2025.doi: 10.1007/s00535-025-02300-5 (Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Meng Y, Zhou Q, Dian Y, Zeng F, Deng G and
Chen X: Ferroptosis: A targetable vulnerability for melanoma
treatment. J Invest Dermatol. 145:1323–1344. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Hsu CY, Al-Hasnaawei S, Kumar A, Ballal S,
Mahmood AA, Kalia R, Joshi KK, Ray S and Pramanik A: Exosomal
non-coding RNA as a key mediator of ferroptosis in lung cancer.
Cell Signal. 136:1121352025. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Chen W, Han L, Wang J and Song L:
Ferroptosis: The dawn of reversing drug resistance in digestive
cancers. Genes Dis. 10:1018732025. View Article : Google Scholar
|
